Menu ×

HEALTHCARE & PHARMACEUTICAL

Classic Familial Adenomatous Polyposis Drugs Market Segmentation by Treatment Type {Minimal Invasive Colorectal Surgery, and Follow-Up Treatment (Colonoscopy, Upper Endoscopy, and Others)}; by Drug Type (Monotherapy, and Combination Therapy Drugs); by Distribution Channel (Hospital, Retail, and Online Pharmacy) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Classic Familial Adenomatous Polyposis Drugs Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

·  September, 2020: Cancer Prevention Pharmaceuticals submitted a new Drug Application to the U.S. Food and Drug Administration (FDA) for CPP-1X/sul for treating familial adenomatous polyposis (FAP) among adults.

Classic Familial Adenomatous Polyposis Drugs Market Highlights 2020 – 2030

The classic familial adenomatous polyposis (FAP) drugs market is estimated to garner a large revenue by growing at a modest CAGR over the forecast period, i.e., 2021 – 2030. The growth of the market can be attributed to factors such as the increasing prevalence of colorectal cancer in the world, a personal history of colorectal diseases or polyposis, and growing cases of inherited disorders that heighten the risk of classic FAP. Colorectal cancer is one of the most commonly occurring cancer in the world. In 2018, it was calculated that approximately 1.9 million people globally suffered from the disease. Additionally, excessive intake of tobacco, unhealthy diet and low indulgence in physical activities are considered to be the main causes of FAP. The incidences of sedentary lifestyle are witnessing a notable hike since the last decade, which in turn is expected to drive market growth in the coming years.

Classic Familial Adenomatous Polyposis Drugs Market

The market is segmented by drug type into monotherapy drugs and combination therapy drugs, out of which, the segment for monotherapy drugs is anticipated to hold the largest share in the classic familial adenomatous polyposis drugs market during the forecast period on account of their lesser number of adverse effects, reduced treatment costs, better tolerability and enhanced compliance with treatment. Moreover, on the basis of distribution channel, the hospital pharmacy segment is projected to occupy a significant market share in the near future, which can be credited to the increased interaction of prescribers and health professionals in hospitals, improved access to medical records of patients and better input in making effective prescribing decisions about drugs. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Classic Familial Adenomatous Polyposis Drugs Market Regional Synopsis

On the basis of geographical analysis, the classic familial adenomatous polyposis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. The market in the North America region is estimated to grab the largest market share over the forecast period on the back of high spending in the healthcare sector, growing occurrence of the disease in the United States and ongoing technological advancements to develop effective cure for colorectal disorders. It is evaluated that FAP affects more than 49, 000 families in the United States. FAP occurs in approximately 1 in every 7000 to 10000 individuals in the country. Furthermore, strong presence of major pharmaceutical companies is also evaluated to drive market growth in the region. Similarly, Europe’s market is also assessed to gather a large market share owing to the growing investments of key players for drug development in the region.

The classic familial adenomatous polyposis drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the classic familial adenomatous polyposis drugs market includes the following segments:

By Treatment Type

  • Minimal Invasive Colorectal Surgery
  • Follow-Up Treatment
    • Colonoscopy
    • Upper Endoscopy
    • Others

By Drug Type

  • Monotherapy Drugs
  • Combination Therapy Drugs

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Growth Drivers

  • Growing Occurrence of Colorectal Cancer Worldwide
  • Genetic istHHiHistory of Polyposis or Colorectal Disorders

Challenges

  • High Treatment Cost of Classic Familial Adenomatous Polyposis 

Top Featured Companies Dominating the Market

  • Adhera Therapeutics, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Cancer Prevention Pharmaceuticals, Inc.
  • Haihe Biopharma Co., Ltd.
  • StemSynergy Therapeutics, Inc.
  • SLA Pharma AG
  • DNAlite Therapeutics Inc
  • GLW International
  • TherapyX Inc
  • Thetis Pharmaceuticals LLC
  • Zikani Therapeutics Inc

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved